PMID- 12686741
OWN - NLM
STAT- MEDLINE
DCOM- 20040413
LR  - 20190910
IS  - 1347-8613 (Print)
IS  - 1347-8613 (Linking)
VI  - 91
IP  - 3
DP  - 2003 Mar
TI  - Stress and vascular responses: anti-inflammatory therapeutic strategy against 
      atherosclerosis and restenosis after coronary intervention.
PG  - 192-6
AB  - Atherosclerosis and restenosis after percutaneous coronary interventions have 
      become major issues in public health in Western countries. Recent studies have 
      revealed that inflammation plays an important role in pathogenesis of 
      cardiovascular diseases. Vascular injury may involve an inflammatory response, 
      which accelerates the recruitment and activation of monocytes through monocyte 
      chemoattractant protein-1 (MCP-1). MCP-1 expression has been shown to be 
      increased in atherosclerotic lesions and balloon injured arteries. Recently, we 
      have devised a new strategy for anti-MCP-1 gene therapy by transfecting mutant 
      MCP-1 gene into skeletal muscle. This mutant MCP-1 has been shown to work as a 
      dominant-negative inhibitor of MCP-1. We here demonstrate that this strategy 
      limited progression of pre-existing atherosclerotic lesions and improved the 
      lesion composition into a more stable phenotype in the hypercholesterolemic mice. 
      This strategy also suppressed monocyte infiltration/activation in the injured 
      site and markedly inhibited restenotic changes (neointimal hyperplasia) in the 
      carotid artery in rabbits, rats, and monkeys after balloon injury or stent 
      implantation. Therefore, MCP-1-mediated monocyte infiltration is essential in the 
      development of restenotic changes as well as atherosclerosis progression. MCP-1 
      can be a practical therapeutic target for human restenosis and atherosclerosis.
FAU - Kitamoto, Shiro
AU  - Kitamoto S
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyushu 
      University, Japan.
FAU - Egashira, Kensuke
AU  - Egashira K
FAU - Takeshita, Akira
AU  - Takeshita A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - J Pharmacol Sci
JT  - Journal of pharmacological sciences
JID - 101167001
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Angioplasty/adverse effects
MH  - Animals
MH  - Arteriosclerosis/pathology/*therapy
MH  - Chemokine CCL2/*antagonists & inhibitors/genetics
MH  - Coronary Restenosis/etiology/pathology/*therapy
MH  - Coronary Vessels/*pathology
MH  - *Genetic Therapy
MH  - Inflammation/pathology/therapy
MH  - Injections, Subcutaneous
MH  - Mice
MH  - Mice, Knockout
MH  - Mutation
MH  - Transfection
RF  - 14
EDAT- 2003/04/11 05:00
MHDA- 2004/04/14 05:00
CRDT- 2003/04/11 05:00
PHST- 2003/04/11 05:00 [pubmed]
PHST- 2004/04/14 05:00 [medline]
PHST- 2003/04/11 05:00 [entrez]
AID - 10.1254/jphs.91.192 [doi]
PST - ppublish
SO  - J Pharmacol Sci. 2003 Mar;91(3):192-6. doi: 10.1254/jphs.91.192.